Received: 4 June 2019
Accepted: 10 June 2019
First Online: 29 June 2019
Compliance with Ethical Standards
: RH has received research funding from Ipsen, Novartis, and Clarity Pharmaceuticals and holds stock in Telix Pharmaceuticals on behalf of his institution.NPT has received consultant/advisory board/honoraria (current/past) from Y-mAbs, Progenics, Bayer, and MedImmune/AstraZeneca and sponsored trials/research support from ImaginAb, Genentech, and Actinium Pharma/FluoroPharma.The other authors declare that they have no conflict of interest.
: This article does not contain any studies with human participants performed by any of the authors.